EverythingALS, a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), announces NeuroSense Therapeutics Ltd (NeuroSense), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS.
EverythingALS was founded in 2020 with the mission of bringing technological innovations and data science to support efforts—from care to cure—for people with ALS. The non-profit conducts technology-based research to help track progression of ALS to be utilized for clinical endpoints. All of the organization’s data and insights from research are made available as open science for researchers, pharmaceutical companies, and other potential partners to collaborate.
NeuroSense is currently enrolling patients in PARADIGM, a Phase IIb double blind, placebo controlled, multicenter clinical trial to evaluate its lead drug candidate for ALS, PrimeC, in Israel and expects to begin patient enrollment in the US and EU this quarter. Top-line results are expected in Q2 2023. PrimeC was tested in a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and demonstrated statistically significant changes in ALS-related biological markers.
In addition to providing financial support for ongoing research projects, NeuroSense’s strategic collaboration with EverythingALS will provide insight into patients’ needs and allow the company to better serve the ALS community.
“We are excited to be working with NeuroSense Therapeutics,” said Indu Navar, Founder of the Peter Cohen Foundation, functioning as EverythingALS. “EverythingALS and NeuroSense are taking similar actions in the fight against neurological diseases, including conducting extensive biomarker research. NeuroSense’s innovative therapeutic approach tackles this complex disease from multiple angles. Collaboration is key to making giant strides toward the digital biomarkers to be used in clinical trials of ALS, and to ultimately work toward the discovery of a potential cure.”
“At NeuroSense, our daily motivation stems from patients and their loved ones, resulting in a patient-centric approach to drug development,” stated Nedira Salzman-Frenkel, VP of Business Development at NeuroSense. “An alliance with EverythingALS, an organization with shared values, supports our mission to develop a disease-modifying therapy. Together, we aim to advance research on biological markers of the disease and deepen the scientific community’s knowledge of the underlying causes.”
Alon Ben Noon, NeuroSense’s CEO will present at EverythingALS’s ALS Expert Series on August 3, 2022 at 4pm PT/7pm ET. In his presentation titled, “NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study” Mr. Ben Noon will review the latest clinical and biomarker data on PrimeC’s efficacy in ALS. “As we prepare to enroll patients in the US and EU for our PARADIGM Phase IIb study, we are increasing our engagement with the international ALS community,” added Mr. Ben Noon.
To listen to Mr. Ben-Noon’s presentation, register here.
[Source(s): NeuroSense, EverythingALS; PR Newswire]
Related Content:
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML
